Biosimilar Blog

For Scientists By Scientists

A comprehensive bioanalytical solution for Denosumab(Prolia®, Xgeva®) 

Bioanalytical Assays to support Denosumab 

Somru developed the following comprehensive list of  bioanalytical assays to support Denosumab biosimilar  development 

  1. Pharmacokinetic Assay (PK) assay 
  2. ADA assay 
  • Binding ADA assay 
  • Cell-based NAb assay(s) 
  • Ligand Binding NAb Assay  
  1. Pharmacodynamic Assays 
  • sCTX 
  • TRAP-5b 
  • P1NP
Read the rest

FDA Roundup

FDA Roundup

Read the rest

Biosimilars Drug Market

Biosimilars Drug Market is poised to grow a Robust CAGR of +14% by 2030 

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product

Read the rest

Lannett Developing Biosimilar

Lannett Developing Biosimilar Insulin Glargine with HEC Group Set to Launch in 2024

As of April 4, 2023, Lannett Company, Inc. is currently in the process of developing a biosimilar insulin glargine product in partnership with the HEC Group of

Read the rest

Biosimilar Market to Surpass

Biosimilar Market to Surpass USD 343,520.90 Million by 2029 at a CAGR of 32.00% 

The comprehensive Biosimilar Market business report is a thorough investigation of current scenario of the global market, which covers several market dynamics. Moreover, for the businesses,

Read the rest

Biosimilars of Denosumab (MAILISHU)

The World’s Second Approved Biosimilars of Denosumab (MAILISHU)

biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection (trade name: MAILISHU, project code: 9MW0311), which is developed by its wholly-owned subsidiary T-mab, has been

Read the rest

Page 1 of 6

Powered by WordPress & Theme by Anders Norén